Enhanced Paclitaxel Efficacy to Suppress Triple-Negative Breast Cancer Progression Using Metronomic Chemotherapy with a Controlled Release System of Electrospun Poly-d-l-Lactide-Co-Glycolide (PLGA) Nanofibers
Open Access
Abstract
Triple-negative breast cancer (TNBC) is highly aggressive and responds poorly to conventional chemotherapy. The challenge of TNBC therapy is to maximize the efficacies of conventional chemotherapeutic agents and reduce their toxicities. Metronomic chemotherapy using continuous low-dose chemotherapy has been proposed as a new treatment option, but this approach is limited by the selection of drugs. To improve antitumor therapeutic effects, we developed electrospun paclitaxel-loaded poly-d-l-lactide-co-glycolide (PLGA) nanofibers as a topical implantable delivery device for controlled drug release and site-specific treatment. The subcutaneously implanted paclitaxel-loaded nanofibrous membrane in mice was compatible with the concept of metronomic chemotherapy; it significantly enhanced antitumor activity, inhibited local tumor growth, constrained distant metastasis, and prolonged survival compared with intraperitoneal paclitaxel injection. Furthermore, under paclitaxel-loaded nanofiber treatment, systemic toxicity was low with a persistent increase in lean body weight in mice; in contrast, body weight decreased in other groups. The paclitaxel-loaded nanofibrous membranes provided sustained drug release and site-specific treatment by directly targeting and changing the tumor microenvironment, resulting in low systemic toxicity and a significant improvement in the therapeutic effect and safety compared with conventional chemotherapy. Thus, metronomic chemotherapy with paclitaxel-loaded nanofibrous membranes offers a promising strategy for the treatment of TNBC.Keywords
Funding Information
- Chang Gung Memorial Hospital (CMRPG3K0281)
This publication has 59 references indexed in Scilit:
- Relapsed Triple-Negative Breast Cancer: Challenges and Treatment StrategiesDrugs, 2013
- Higuchi equation: Derivation, applications, use and misuseInternational Journal of Pharmaceutics, 2011
- Paclitaxel-Eluting Polymer Film Reduces Locoregional Recurrence and Improves Survival in a Recurrent Sarcoma Model: A Novel Investigational TherapyAnnals of Surgical Oncology, 2011
- Metastatic colonization: Settlement, adaptation and propagation of tumor cells in a foreign tissue environmentSeminars in Cancer Biology, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Angiogenesis and Breast CancerJournal of Oncology, 2010
- Weekly paclitaxel in the treatment of recurrent ovarian cancerNature Reviews Clinical Oncology, 2010
- Prevention of Local Tumor Recurrence Following Surgery Using Low-Dose Chemotherapeutic Polymer FilmsAnnals of Surgical Oncology, 2009
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Effects of prolonged versus short-term exposure paclitaxel (Taxol??) on human tumor colonyforming unitsAnti-Cancer Drugs, 1997